National Institutes of Health, Public Health Service, HHS.
The inventions listed below are owned by agencies of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.
Diacylglycerol Compounds Useful as Protein Kinase C Activators and Apoptosis Inducers
Victor E. Marquez, Peter M. Blumberg, Jeewoo Lee, Marcelo Kazanietz (NCI)
DHHS Reference No. E-088-01/0 filed 06 Aug 2001
Licensing Contact: Jonathan Dixon; 301/496-7056 ext. 270; email@example.com
This invention discloses new diacylglycerol (DAG) compounds that may be useful as chemotherapeutic agents. DAG activates many of the isozymes in the Protein Kinase C (PKC) family, a phospholipid-dependent serine/threonine-specific kinase that plays an important role in cellular growth and differentiation. The activation of PKC by DAG is important in mediating the actions of a variety of hormones, neurotransmitters, and other biological control factors. This new class of DAG compounds is proving to be superior at inducing apoptosis in androgen-sensitive LNCaP prostate cancer cells by specifically activating the alpha isozyme. The compounds are believed to receive their superior properties from the replacement of the ester oxygen with a nitrogen attached to a hydroxyl group (N-OH). The presence of the hydroxamate functionality endows the molecule with improved solubility properties making these compounds the most potent and least lipophilic DAG analogues known to date.
Differentiation of Stem Cells to Pancreatic Endocrine Cells
Nadya Lumelsky et al. (NINDS)
Serial No. 60/266,917 filed 06 Feb 2001
Licensing Contact: Norbert Pontzer; 301/496-7736 ext. 284; e-mail: firstname.lastname@example.org
Diabetes, which effects 16 million people in the United States alone, results at least in part from decreased production of insulin by the pancreas. In the pancreas, insulin is produced by specialized structures called the islets of Langerhans. Adult mammalian islets are composed of four major cell types: The α, β, δ and PP cells which produce glucagons, insulin, somatostatin, and pancreatic polypeptides respectively. The physical proximity and resulting interaction of each of these modulators of carbohydrate metabolism may be necessary for the proper control of insulin secretion. The lack of tight feedback control of insulin secretion is thought to be responsible for pathologies arising after the long-term injection of insulin for diabetics.
This invention provides a method for differentiating stem cells into endocrine cells that produce insulin and other pancreatic hormones. The cells self-assemble to form three-dimensional clusters similar in topology to normal pancreatic islets. Glucose triggers insulin release from these cell clusters by mechanisms similar to those employed in vivo. When injected into experimental animals, the insulin producing cells undergo rapid vascularization and maintain an islet-like organization. These cells could provide both a model system for in vitro study of pancreatic islets and a potential therapy for replacing lost pancreatic function through transplantation.Start Signature
Dated: November 6, 2001.
Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.
[FR Doc. 01-28705 Filed 11-15-01; 8:45 am]
BILLING CODE 4140-01-P